MTOR and renal cell carcinoma: Nonetheless, given the propensity of advanced RCC patients to develop resistance to mTOR inhibitors and TKIs, exploration of new targets in glucose metabolism within RCC to counter drug resistance in this patient population represents a promising avenue for future research.